Neringa Balčiūnienė

Dr. Neringa Balčiūnienė


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2025 in Medicina
Verified
Journal Article
Open access
PDF file
SŽSkaistė Žukaitienė
Skaistė Žukaitienė
KBKarolis Bareikis
Karolis Bareikis
SSSimona Stankeviciute
Simona Stankeviciute
AUAkvile Usaite
Akvile Usaite
NBNeringa Balčiūnienė
Neringa Balčiūnienė
RMRomaldas Mačiulaitis
Romaldas Mačiulaitis
Background and Objectives: Post-surgical central nervous system (CNS) infections are severe complications associated with high morbidity and mortality. Vancomycin is a key antibiotic used in their management. However, because of the restrictive properties of the blood–brain barrier (BBB), plasma concentrations may not accurately reflect drug exposure in the brain extracellular fluid (ECF), the presumed site of infection. Cerebral microdialysis enables direct measurement of unbound drug levels in brain ECF. This study aimed to assess vancomycin penetration into brain ECF in patients with suspected or confirmed post-surgical CNS infection. Materials and Methods: Five patients with suspected or confirmed post-surgical CNS infections were enrolled. Paired brain ECF microdialysate and plasma samples (and cerebrospinal fluid (CSF) samples, when available) were collected over two consecutive days at vancomycin steady state. Vancomycin concentrations were determined using a homogeneous enzyme immunoassay and corrected for probe recovery based on in vitro calibration. Pharmacokinetic parameters, including mean concentrations and 24-h area under the concentration–time curve (AUC24), were calculated for plasma and ECF, and ECF-to-plasma ratios were derived. Results: Two subgroups could be identified: patients with negligible ECF concentrations (“low penetrators”), and those with higher ECF levels (“high penetrators”). Mean (SD) ECF-to-plasma concentration ratios were 0.07 (0.04) in “low penetrators” and 0.44 (0.10) in “high penetrators”. The corresponding AUC24 ratios were 0.06 (0.03) and 0.40 (0.03), respectively. The presence of systemic inflammatory response syndrome (SIRS) was considered the most plausible factor differentiating these two subgroups. Conclusions: Vancomycin exposure in brain ECF demonstrated substantial interpatient variability in post-surgical CNS infections, with some patients showing minimal drug penetration.

21 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SŽSkaistė Žukaitienė
Skaistė Žukaitienė
KBKarolis Bareikis
Karolis Bareikis
SSSimona Stankevičiūtė
Simona Stankevičiūtė
AŪAkvilė Ūsaitė
Akvilė Ūsaitė
JPJolita Pancerė
Jolita Pancerė
RMRomaldas Mačiulaitis
Romaldas Mačiulaitis
Background/Objectives: Postoperative central nervous system (CNS) infections are severe compli-cations of neurosurgery, and vancomycin is a cornerstone of empirical and targeted therapy; how-ever, longitudinal vancomycin exposure in this population is poorly characterized. Methods: We conducted a single-centre retrospective cohort study of 189 postoperative CNS infection episodes in 174 adults treated between 2020 and 2026, focusing on longitudinal vancomycin exposure and pharmacokinetic.pharmacodynamic (PK/PD) target attainment according to therapeutic drug mon-itoring (TDM) status. A population pharmacokinetic (PopPK) model, developed from 193 concen-trations was used to reconstruct exposure in TDM episodes and simulate exposure for no TDM ep-isodes. Results: The final PopPK model confirmed creatinine clearance (CrCl) as the principal de-terminant of vancomycin clearance; higher baseline CrCl independently predicted a greater propor-tion of treatment time with AUC24 <400 mg·h/L. Underexposure occurred throughout: patients spent 37.2% (TDM) and 47.5% (no TDM) of evaluable treatment time below AUC24 400 mg·h/L, with early underexposure even more common in both groups. The TDM group spent more time within the AUC₂₄ 400–600 mg·h/L range (43.23% vs 29.91%). No statistically significant exposure–outcome associations were identified in the overall population. In an exploratory ICU subgroup analysis, higher mean AUC₂₄ was associated with clinical improvement within 72 h (OR 1.92 per 100 mg·h/L increase, 95% CI 1.12–3.28), although the exposure-by-ICU interaction was not statistically signifi-cant. Conclusions: These findings support early and repeated vancomycin TDM throughout treat-ment to identify and address underexposure, particularly in patients with augmented renal function and those treated in ICU.